跳至主要内容
临床试验/NCT03874260
NCT03874260Unknown4 期

A Multi-center, Randomized, Double-blind, Parallel Phase Ⅳ Study to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

Daewon Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2018年7月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
180
试验地点
1
主要终点
rate of change for Triglyceride based on baseline

研究概览

简要总结

A Multi-center, Randomized, Double-blind, Parallel Phase Ⅳ Study to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • both male and female who are over 19-year-old
  • 200mg/dl≤TG<500mg/dl
  • Desired value of LDL-c
  • very high risk < 70
  • high risk < 100
  • moderate risk <130
  • low risk < 160

排除标准

  • patient who is going to have an operation during this study
  • patient who has allergy or hypersensitivity of fenofibrate
  • patient who has abnormal ECG

研究组 & 干预措施

statin / fenofibrate

Experimental

stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O

干预措施: Fenofibrate (Drug)

statin / fenofibrate placebo

Placebo Comparator

stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O

干预措施: Fenofibrate (Drug)

结局指标

主要结局

rate of change for Triglyceride based on baseline

时间窗: 8week

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验